SUGAR Trial Finds Superior Stent for Those With Diabetes and CAD

Target-lesion failures at 1 year were less common in diabetic patients treated with the polymer-free Cre8 EVO drug elution stent, compared to Resolute Onyx DES.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Spanish ,Gennaro Sardella ,Marc Etienne Jolicoeur ,Rafael Romaguera ,David Kandzari ,Ablative Solutions ,Bellvitge University Hospital ,Boston Scientific ,Piedmont Hart Institute ,Sapienza University Of Rome ,Icahn School Of Medicine At Mount Sinai ,Cardiovascular Research Technologies ,Medtronic ,Duke University ,Spanish Society Of Cardiology ,Cardiovascular Research Foundation ,Resolute Onyx ,Second Generation Drug Eluting Stents ,Transcatheter Cardiovascular Therapeutics ,Cardiovascular Research ,Employed All Comer Design ,Gregg Stone ,Icahn School ,Mount Sinai ,Sapienza University ,European Heart Journal ,Spanish Society ,Stent ,Diabetes Mellitus ,Acute Coronary Syndrome Acs ,Cute Coronary Syndrome ,Cs ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Atherosclerosis ,Lipids ,Ipid Management ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Myocardial Infarction ,Onstemi ,On St Segment Elevation Mi ,On St Segment Eleva ,